201 related articles for article (PubMed ID: 33437948)
21. Comparing the ICERs in Medicine Reimbursement Submissions to NICE and PBAC-Does the Presence of an Explicit Threshold Affect the ICER Proposed?
Wang S; Gum D; Merlin T
Value Health; 2018 Aug; 21(8):938-943. PubMed ID: 30098671
[TBL] [Abstract][Full Text] [Related]
22. A comparative analysis of two contrasting European approaches for rewarding the value added by drugs for cancer: England versus France.
Drummond M; de Pouvourville G; Jones E; Haig J; Saba G; Cawston H
Pharmacoeconomics; 2014 May; 32(5):509-20. PubMed ID: 24599784
[TBL] [Abstract][Full Text] [Related]
23. The evolution of ICER's review process for new medical interventions and a critical review of economic evaluations (2018-2019): how stakeholders can collaborate with ICER to improve the quality of evidence in ICER's reports.
Ronquest NA; Paret K; Gould IG; Barnett CL; Mladsi DM
J Manag Care Spec Pharm; 2021 Nov; 27(11):1601-1612. PubMed ID: 34714108
[No Abstract] [Full Text] [Related]
24. Accounting for inflation within NICE cost-effectiveness thresholds.
Low V; Macaulay R
Expert Rev Pharmacoecon Outcomes Res; 2022 Jan; 22(1):131-137. PubMed ID: 33980118
[TBL] [Abstract][Full Text] [Related]
25. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
[TBL] [Abstract][Full Text] [Related]
26. Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal.
Boyers D; Jia X; Jenkinson D; Mowatt G
Pharmacoeconomics; 2012 Jun; 30(6):483-95. PubMed ID: 22480381
[TBL] [Abstract][Full Text] [Related]
27. The cost-effectiveness of public health interventions examined by the National Institute for Health and Care Excellence from 2005 to 2018.
Owen L; Fischer A
Public Health; 2019 Apr; 169():151-162. PubMed ID: 30885422
[TBL] [Abstract][Full Text] [Related]
28. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
[TBL] [Abstract][Full Text] [Related]
29. Some inconsistencies in NICE's consideration of social values.
Paulden M; O'Mahony JF; Culyer AJ; McCabe C
Pharmacoeconomics; 2014 Nov; 32(11):1043-53. PubMed ID: 25145802
[TBL] [Abstract][Full Text] [Related]
30. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
[TBL] [Abstract][Full Text] [Related]
31. Trabectedin for the treatment of advanced metastatic soft tissue sarcoma: a NICE single technology appraisal.
Rafia R; Simpson E; Stevenson M; Papaioannou D
Pharmacoeconomics; 2013 Jun; 31(6):471-8. PubMed ID: 23568332
[TBL] [Abstract][Full Text] [Related]
32. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
[TBL] [Abstract][Full Text] [Related]
33. Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective.
Dunlop W; van Keep M; Elroy P; Perez ID; Ouwens MJNM; Sarbajna T; Zhang Y; Greystoke A
Pharmacoecon Open; 2022 Mar; 6(2):241-252. PubMed ID: 34532842
[TBL] [Abstract][Full Text] [Related]
34. For Whom the Price Escalates: High Price and Uncertain Value of Cancer Drugs.
Shin G; Kwon HY; Bae S
Int J Environ Res Public Health; 2022 Apr; 19(7):. PubMed ID: 35409887
[TBL] [Abstract][Full Text] [Related]
35. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Morgan P; Woolacott N; Biswas M; Mebrahtu T; Harden M; Hodgson R
Pharmacoeconomics; 2017 Sep; 35(9):909-919. PubMed ID: 28342113
[TBL] [Abstract][Full Text] [Related]
36. Design of patient access schemes in the UK: influence of health technology assessment by the National Institute for Health and Clinical Excellence.
Jarosławski S; Toumi M
Appl Health Econ Health Policy; 2011 Jul; 9(4):209-15. PubMed ID: 21682349
[TBL] [Abstract][Full Text] [Related]
37. The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson's disease.
Jørgensen J; Servos S; Kefalas P
J Mark Access Health Policy; 2018; 6(1):1500419. PubMed ID: 30364868
[No Abstract] [Full Text] [Related]
38. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.
Clement FM; Harris A; Li JJ; Yong K; Lee KM; Manns BJ
JAMA; 2009 Oct; 302(13):1437-43. PubMed ID: 19809025
[TBL] [Abstract][Full Text] [Related]
39. What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10,000/QALY?
Carroll C; Houten R; Boland A; Kaltenthaler E; Dickson R
Value Health; 2018 Mar; 21(3):341-350. PubMed ID: 29566842
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]